<DOC>
	<DOCNO>NCT00875784</DOCNO>
	<brief_summary>This study evaluate exposure sumatriptan administration TREXIMA ( sumatriptan 85mg/naproxen sodium 500mg ) follow subcutaneous IMITREX injection ( 4mg 6mg ) 2 hour later compare administration IMITREX 100mg tablet follow IMITREX 100mg tablet 2 hour later .</brief_summary>
	<brief_title>An Open-label , Randomized , 3-period Crossover Study Evaluate Sumatriptan Pharmacokinetics TREXIMA™ ( Sumatriptan Succinate / Naproxen Sodium ) Tablet Followed IMITREX® ( Sumatriptan Succinate )</brief_title>
	<detailed_description>An open-label , randomize , 3-period crossover study evaluate sumatriptan pharmacokinetics TREXIMA™ ( sumatriptan succinate / naproxen sodium ) Tablet follow IMITREX® ( sumatriptan succinate ) Injection 4mg administer use IMITREX STATdose System® TREXIMA tablet follow IMITREX® ( sumatriptan succinate ) Injection 6mg administer use IMITREX STATdose System® compare IMITREX Tablet 100mg follow IMITREX Tablet 100mg .</detailed_description>
	<mesh_term>Migraine Disorders</mesh_term>
	<mesh_term>Naproxen</mesh_term>
	<mesh_term>Sumatriptan</mesh_term>
	<criteria>Healthy adult male females 18 55 year age , inclusive . Healthy subject define individual free clinically significant illness disease determine medical history , physical examination , laboratory study test . Female subject nonchildbearing potential Any subject take oral contraceptive stable regimen least 2 month prior screen . BMI : 2030 kg/m2 , inclusive . Subject willing able provide write informed consent . Subjects suffer migraine attack . Subject confirm suspected ischemic heart disease ; angina pectoris , history myocardial infarction , document silent ischemia , Prinzmetal 's anginacoronary vasospasm , sign , symptom consistent . Subject evidence history ischemic abdominal syndrome , peripheral vascular disease Raynaud 's syndrome . Subject cardiac arrhythmia require medication history clinically significant electrocardiogram abnormality , investigator 's opinion , contraindicate participation study . Subject history cerebrovascular pathology include stroke and/or transient ischemic attack . Subject history congenital heart disease . Subject hypertension screening . Subject , investigator 's opinion , likely unrecognized cardiovascular cerebrovascular disease . Subject history epilepsy structural brain lesion lower convulsive threshold treat antiepileptic drug seizure control within 5 year prior screen . History impaired hepatic renal function . Subject currently take take previous 4 week , herbal preparation contain St. John 's Wort . Use prescription nonprescription drug , vitamin , herbal dietary supplement , within 7 day prior first dose study medication . Note : Excluded list : acetaminophen dos less equal 2 gram per day contraceptive . Subject hypersensitivity , intolerance , contraindication use sumatriptan naproxen sodium component 5HT1 receptor agonist . Subject history gastrointestinal surgery specifically indicate past history bleeding , ulceration perforation . Subject history gastric bypass stapling surgery . Subject history GI ulceration past six month gastrointestinal bleeding past year . Subject history inflammatory bowel disease . Treatment investigational drug within 30 precede first dose study medication . Positive serum betahuman chorionic gonadotropin test female . Pregnant , actively try become pregnant breastfeeding . Subjects history drug alcohol abuse . History regular alcohol consumption exceed 7 drink per week female 14 drink per week men within 6 month screen . Positive urine drug screen include alcohol screening . Donation blood excess 500 mL within 56 day prior first dose study medication . Subjects smoke 10 cigarette per day . History sensitivity heparin , heparininduced thrombocytopenia sensitivity study medication component thereof .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Sumatriptan exposure</keyword>
</DOC>